Before revision:  These results support the study of  -AR antagonists for  reducing mortality in pneumonia and ARDS and highlight the need for prospective trials of   -AR antagonists to assess their efficacy in preventing cytokine storm  and death in COVID-19.
After revision:  These results support the study of -AR antagonists for reducing mortality in pneumonia and acute respiratory distress, as well as highlight the need for prospective trials of  -AR antagonists to assess their efficacy in preventing cytokine storm and death in COVID-19.